Shares of Cronos Group were sailing higher this week after Bank of America Merrill Lynch decided to give the marijuana company a two-notch upgrade.

The bank has argued that a move into the U.S. CBD market could be a huge opportunity for the company.

Shares of the stock saw a gain of nearly 16% after Wall Street learned of the upgrade.

Analyst Christopher Carey boosting his rating on the stock to buy from under-perform, which had been based on valuation. He has a 12-month price target of C$27/US$20 per share, up from C$17/US$13.

Cronos CEO Mike Gorenstein recently said that the Canadian cannabis company will be “aggressive” regarding a U.S. CBD launch.

Speaking at a luncheon hosted by the Consumer Analyst Group of New York (CAGNY), Gorenstein said hes not talking “that long of a way out” regarding the company’s entry into the U.S. market.

Shares of Cronos have seen gains of 49% so far this year and have seen a whopping move of 95% in the past 12 months.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Marijuana Is The Most Common Drug Used By These Workers
26 June 2017
Brazil Senate Committee Approves Bill for Medical Marijuana
30 November 2018
California is Being Sued by Many Cities Over Marijuana Home Deliveries
06 April 2019